Table 4.

Analysis of prognostic factors

Feature	N	5-yr OS ±SE (%)	p	5-yr EFS ±SE (%)	p
Sex			0.274		0.321
Female	52	55.8 ± 6.8		50.0 ± 6.8
Male	50	44.0 ± 7.0		38.0 ± 6.9
Race			0.277		0.272
Black	19	36.8 ± 10.4		31.6 ± 9.9
Other	19	68.4 ± 10.3		63.2 ± 10.6
White	64	48.4 ± 6.2		42.2 ± 6.2
Cytogenetics			0.811		0.528
inv(16)	7	71.4 ± 15.6		71.4 ± 15.6
t(8;21)	11	36.4 ± 13.0		36.4 ± 13.0
t(9;11)	14	57.1 ± 12.5		57.1 ± 12.5
Other 11q23	12	50.0 ± 13.4		41.7 ± 13.0
Normal	18	55.6 ± 11.7		33.3 ± 11.1
Other	39	46.2 ± 7.8		43.6 ± 7.7
CNS status			0.367		0.338
CNS-negative	69	51.7 ± 5.4		46.0 ± 5.3
CNS-positive	12	40.0 ± 11.7		33.3 ± 11.1
FAB			0.882		0.837
M0/other	7	57.1 ± 16.7		42.9 ± 16.2
M1	18	44.4 ± 11.7		38.9 ± 11.5
M2	22	45.5 ± 10.1		36.4 ± 9.7
M4/M4Eo	20	45.0 ± 10.6		40.0 ±10.3
M5	18	66.7 ± 10.7		61.1 ± 11.0
M7	16	50.0 ± 11.8		50.0 ± 11.8
MRD after window			0.058		0.029
< 0.1%	21	66.7 ± 10.3		66.7 ± 10.3
≥ 0.1%	20	40.0 ± 10.3		35.0 ± 10.0
MRD after DAV #1			0.024		0.003
< 0.1%	27	63.0 ± 9.3		59.3 ± 9.5
≥ 0.1%	17	35.3 ± 10.7		23.5 ± 9.2
MRD after DAV #2			0.055		0.064
< 0.1%	26	69.2 ± 9.1		65.4 ± 9.3
≥ 0.1%	10	40.0 ± 13.9		40.0 ± 13.9
Age >10			0.003		0.002
Yes	47	34.0 ± 6.9		27.7 ± 6.5
No	55	63.6 ± 6.4		58.2 ± 6.5
Age (continuous)			0.003		0.002
Leukocyte count >50			0.316		0.228
Yes	24	37.5 ± 9.4		33.3 ± 9.1
No	78	53.8 ± 5.6		47.4 ± 5.7
Leukocyte count (continuous)			0.282		0.110